An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides

An LNA-amide modification that enhances the cell uptake and activity of phosphorothioate exon-skipping oligonucleotides

Oligonucleotides that target mRNA have great promise as therapeutic agents for life-threatening conditions but suffer from poor bioavailability, hence high cost. As currently untreatable diseases come within the reach of oligonucleotide therapies, new analogues are urgently needed to address this. W...

Full description

Bibliographic Details
Main Authors:	Baker, YR, Thorpe, C, Chen, J, Poller, LM, Cox, L, Kumar, P, Lim, WF, Lie, L, McClorey, G, Epple, S, Singleton, D, McDonough, MA, Hardwick, JS, Christensen, KE, Wood, MJA, Hall, JP, El-Sagheer, AH, Brown, T
Format:	Journal article
Language:	English
Published:	Springer Nature 2022

Similar Items

Synthesis and biophysical properties of carbamate-locked nucleic acid (LNA) oligonucleotides with potential antisense applications
by: Thorpe, C, et al.
Published: (2019)

Advancing the potential of peptide-PMO compounds in exon skipping therapy for DMD
by: Godfrey, C, et al.
Published: (2012)

Covalently attached intercalators restore duplex stability and splice-switching activity to triazole-modified oligonucleotides
by: Dysko, A, et al.
Published: (2022)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
by: Aoki, Y, et al.
Published: (2012)

Exon skipping is correlated with exon circularization
by: Kelly, S, et al.
Published: (2015)

Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties
by: Chwalenia, K, et al.
Published: (2022)

Cell-penetrating peptides to enhance delivery of Oligonucleotide-based therapeutics
by: McClorey, G, et al.
Published: (2018)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
by: Aoki, Y, et al.
Published: (2011)

Synthesis and Properties of Oligonucleotides Containing LNA-Sulfamate and Sulfamide Backbone Linkages
by: Zengin Kurt, B, et al.
Published: (2024)

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.
by: Wang, Q, et al.
Published: (2010)

Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
by: Betts, C, et al.
Published: (2018)

Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy
by: Blain, A, et al.
Published: (2018)

Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.
by: Betts, C, et al.
Published: (2012)

Novel EGFP reporter cell and mouse models for sensitive imaging and quantification of exon skipping
by: Hara, Y, et al.
Published: (2020)

Modulation of interleukin 1 beta gene expression using antisense phosphorothioate oligonucleotides.
by: Manson, J, et al.
Published: (1990)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.
by: Yin, H, et al.
Published: (2011)

Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice
by: Yin, H, et al.
Published: (2011)

Context dependent effects of chimeric peptide morpholino conjugates contribute to dystrophin exon-skipping efficiency
by: Yin, HF, et al.
Published: (2016)

Backbone-modified oligonucleotides for biology and medicine
by: Epple, S
Published: (2021)

CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion
by: Yin, Hao, et al.
Published: (2019)

Fine tuning of phosphorothioate inclusion in 2'-O-methyl oligonucleotides contributes to specific cell targeting for splice-switching modulation
by: Aoki, Y, et al.
Published: (2021)

Development of LNA gapmer oligonucleotide-based therapy for ALS/FTD caused by the C9orf72 repeat expansion
by: Sathyaprakash, C, et al.
Published: (2020)

Design and application of bispecific splice-switching oligonucleotides.
by: Bestas, B, et al.
Published: (2014)

In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.
by: Aoki, Y, et al.
Published: (2010)

Analysis of coordinated skipped exon pairs using single molecule sequencing technology
by: Adadey, Asa (Asa Owuraku)
Published: (2015)

Machine learning based CRISPR gRNA design for therapeutic exon skipping
by: Louie, Wilson, et al.
Published: (2022)

Machine learning based CRISPR gRNA design for therapeutic exon skipping
by: Louie, Wilson,M. Eng.Massachusetts Institute of Technology.
Published: (2020)

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
by: Lu, Q, et al.
Published: (2003)

Optimizing anti-gene oligonucleotide 'Zorro-LNA' for improved strand invasion into duplex DNA.
by: Zaghloul, E, et al.
Published: (2011)

Use of antisense-mediated exon skipping to generate dystrophin in muscles of the mdx dystrophic mouse
by: Lu, Q, et al.
Published: (2004)

Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
by: Betts, C, et al.
Published: (2014)

Amplification of antibody production by phosphorothioate oligodeoxynucleotides.
by: Branda, R, et al.
Published: (1996)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
by: Goyenvalle, A, et al.
Published: (2010)

Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
by: Aoki, Y, et al.
Published: (2012)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
by: Goyenvalle, A, et al.
Published: (2011)

Rescu of severely affected dystrophin/utrophin deficient mice by morpholino-oligomer mediated exon skipping
by: Goyenvalle, A, et al.
Published: (2010)

Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
by: Gait, M, et al.
Published: (2018)

Immortalized canine dystrophic myoblast cell lines for development of peptide-conjugated splice-switching oligonucleotides
by: Tone, Y, et al.
Published: (2021)

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
by: Yokota, T, et al.
Published: (2012)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
by: Goyenvalle, A, et al.
Published: (2009)